ArticleJournal of clinical and experimental hepatology
Stanozolol-induced Liver Injury: A Distinctive Cholestatic Clinical and Biochemical Phenotype at Presentation.
Article in Journal of clinical and experimental hepatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Multi-omics analysis reveals that Danggui Buxue decoction ameliorates benzene-induced blood deficiency syndrome via the restoration of hematopoietic lineage and remodeling of the immune microenvironment.Chinese medicine · 2026Article
- Liver Injury Associated With Irregular Herbal Products: A Translational Case Series With Chemical Authentication and Causality Assessment Using the Updated RUCAM.Case reports in hepatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & aims: The misuse of Anabolic Androgenic Steroids (AAS), including Stanozolol, for performance enhancement has emerged as a significant cause of liver damage. This study aims to elucidate the distinctive hepatotoxicity profiles induced by Stanozolol. Methods: Eighteen individuals were prospectively evaluated by the Latin American DILI Registry from 2013 to 2023. Data regarding Stanozolol administration, symptoms onset, and clinical manifestations were collected. Comprehensive assessments including serologies, abdominal imaging, and in some cases, liver biopsies were performed to identify Stanozolol-induced liver injury and exclude other etiologies. Results: All patients were young males aged between 19 and 48, utilizing Stanozolol for aesthetic purposes. The mean latency to symptom onset was 55 days. Predominant symptoms included jaundice and pruritus. Elevated total bilirubin levels were observed in all cases, while gamma-glutamyl transferase levels remained within or slightly above normal ranges. Concurrent use of other substances was reported in ten cases, showcasing a trend of poly-substance abuse. Conclusions: The study identified a specific biochemical profile of Stanozolol-induced liver injury in young men using it for aesthetic purposes. The characteristic liver injury profile has marked elevation of bilirubin, mild rise in transaminases, and near-normal GGT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.